+8%

est. 2Y upside i

HealthcareSeries A

Rank

#3342

Sector

Healthcare AI Software

Est. Liquidity

~5Y

Data Quality

Data: Medium

DeepScribe is a high-risk equity bet: $60M in liquidation preferences sits above a $43.9M current valuation, meaning common stock has zero intrinsic value today and any exit below $60M leaves employees with nothing.

Last updated: May 14, 2026

Bull (10%)+300%

DeepScribe captures specialty AI documentation leadership in oncology and cardiology, scaling ARR from $14.6M to $45M+ by 2028 via partnerships like Flatiron Health. A strategic acquisition at $200-250M or a strong Series B at a similar valuation clears the $60M preference stack and delivers meaningful common-stock upside.

Base (45%)+30%

Steady specialty-vertical expansion grows ARR to ~$22M by end of 2027, enabling a Series B at $90-110M valuation that finally reprices common equity above zero. Dilution from the new preferred round and the existing $60M overhang constrain common returns to modest levels.

Bear (45%)-80%

Microsoft Nuance DAX and native Epic AI features commoditize ambient scribing, stalling DeepScribe near current $14.6M ARR with no clear path to a Series B. Cash constraints force an acqui-hire or distressed sale at or below the $60M liquidation preference, leaving common stockholders with near-zero recovery.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

137%

$60M in total liquidation preferences exceeds the $43.9M current valuation by $16.1M, meaning preferred shareholders capture 100% of exit proceeds at any sale at or below today's implied value, leaving common at zero.

Dilution Risk

high

A future Series B—likely necessary given 3+ years without new capital and an unproven path to profitability—will issue additional preferred shares that further subordinate existing common equity and expand the preference stack.

Secondary Liquidity

none

No secondary market activity or company-sponsored tender offers have been reported; shares are fully illiquid private-company stock for the foreseeable future.

View all 2 open roles at DeepScribe →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on DeepScribe's data — designed to show you've done your homework.

  • 1

    “As Epic and Microsoft Nuance DAX bundle ambient scribing natively at no add-on cost, what is DeepScribe's durable pricing power and switching-cost strategy for retaining health system contracts?”

  • 2

    “What is the current net revenue retention rate across customer cohorts, and how does churn differ between large health systems like Ochsner and smaller specialty practices?”

  • 3

    “What is the board's current stance on a Series B versus a path to profitability, and what is the company's runway at the current burn rate given no outside capital since January 2022?”

Community

Valuation Sentiment

Our model estimates +8% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.